Novavax coronavirus vaccine found 89 per cent effective in trials

New Scientist Default Image

A scientist working on vaccine development at the Novavax lab in Gaithersburg, Maryland


A coronavirus vaccine developed by the US firm Novavax has been shown to be 89 per cent effective in preventing covid-19 in phase III clinical trials.

The vaccine is made from nanoparticles containing spike proteins from the virus, which are produced by genetically modified insect cells. The nanoparticles cannot replicate or cause covid-19, but they enable the body’s immune system to recognise the viral proteins and make antibodies against them.

The vaccine is given as two doses, but unlike the Pfizer/BioNTech …

More Stories
The Pharaohs’ Golden Parade: Ancient Egyptian mummies will be honored in procession through Cairo